Northwest Biotherapeutics, Inc. reported a net loss of $60.2 million for the fiscal year ending December 31, 2025, a decrease from the $83.8 million loss recorded in 2024. The company’s total revenues remained relatively stable, with a slight decline to $1.4 million from $1.4 million in the previous year. The reduction in net loss was attributed to lower research and development expenses, which fell to $28.8 million from $34.9 million, primarily due to decreased stock-based compensation and costs associated with the Marketing Authorization Application (MAA) process for its lead product, DCVax®-L.
In 2025, Northwest Biotherapeutics made significant strategic moves, including the acquisition of Advent BioServices, which was completed on October 24, 2025. This acquisition is expected to enhance the company’s manufacturing capabilities and operational efficiencies. The company also submitted a MAA for DCVax-L for glioblastoma in December 2023, and is currently engaged in the regulatory review process. Additionally, the company is preparing for future clinical trials of its second product, DCVax®-Direct, which targets inoperable solid tumors.
Operationally, the company expanded its workforce significantly, increasing from 25 full-time employees at the beginning of 2025 to 105 by year-end, largely due to the Advent acquisition. The company also reported a total of 1.6 billion shares of common stock outstanding as of March 31, 2026, reflecting its ongoing efforts to raise capital through equity financing. The company’s cash and cash equivalents increased to $3.0 million by the end of 2025, up from $2.2 million in 2024, indicating a slight improvement in liquidity.
Looking ahead, Northwest Biotherapeutics faces challenges related to its ongoing need for capital to fund operations and clinical trials. The company has expressed substantial doubt about its ability to continue as a going concern without securing additional financing. Management has indicated that it will continue to seek equity and debt financing to support its operations until it can generate sufficient revenue from product sales. The company’s future performance will largely depend on the successful commercialization of its DCVax products and the outcomes of its clinical trials.
About NORTHWEST BIOTHERAPEUTICS INC
Northwest Biotherapeutics is a biotechnology company specializing in personalized immune therapies for cancer. Its platform, DCVax, uses a patient’s own dendritic cells to target solid tumors, with products like DCVax-L for surgically removable cancers and DCVax-Direct for inoperable tumors. The company focuses on immunotherapy development, manufacturing, and regulatory approval, primarily serving cancer patients worldwide. It emphasizes innovation, patent protection, and strategic collaborations in the competitive cancer treatment market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.